Edwin DeJesus

Summary

Publications

  1. pmc Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment
    Philip H Keiser
    University of Texas Southwestern Medical Center, Dallas, Texas, USA
    BMC Infect Dis 5:2. 2005
  2. ncbi Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults
    Edwin DeJesus
    IDC Research, Altamonte Springs, FL 32701, USA
    Clin Infect Dis 39:1038-46. 2004
  3. ncbi Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects
    Edwin DeJesus
    Infectious Disease Consultants, Altamonte Springs, Florida 32701, USA
    J Infect Dis 188:1009-16. 2003
  4. ncbi Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial
    Edwin DeJesus
    IDC Research Initiative, Altamonte Springs, FL, USA
    Clin Infect Dis 39:411-8. 2004
  5. doi Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    Lancet 379:2429-38. 2012
  6. doi Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    Antivir Ther 15:711-20. 2010
  7. doi Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
    Roberto Ortiz
    Orlando Immunology Center, Orlando, Florida, USA
    AIDS 22:1389-97. 2008
  8. ncbi Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study
    Richard Elion
    George Washington University, Washington, DC, USA
    HIV Clin Trials 7:324-33. 2006
  9. ncbi Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    J Acquir Immune Defic Syndr 43:1-5. 2006
  10. ncbi Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis
    Anton L Pozniak
    Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 43:535-40. 2006

Detail Information

Publications43

  1. pmc Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment
    Philip H Keiser
    University of Texas Southwestern Medical Center, Dallas, Texas, USA
    BMC Infect Dis 5:2. 2005
    ..Hyperlipidemia secondary to protease inhibitors (PI) may abate by switching to anti-HIV medications without lipid effects...
  2. ncbi Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults
    Edwin DeJesus
    IDC Research, Altamonte Springs, FL 32701, USA
    Clin Infect Dis 39:1038-46. 2004
    ..Evaluating other unique nucleoside reverse-transcriptase inhibitor (NRTI) combinations for long-term viral suppression is desirable...
  3. ncbi Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects
    Edwin DeJesus
    Infectious Disease Consultants, Altamonte Springs, Florida 32701, USA
    J Infect Dis 188:1009-16. 2003
    ..There were no episodes of thrombotic microangiopathy. Valacyclovir was safe and effective for the suppression of recurrent genital herpes infection in HIV-infected individuals...
  4. ncbi Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial
    Edwin DeJesus
    IDC Research Initiative, Altamonte Springs, FL, USA
    Clin Infect Dis 39:411-8. 2004
    ..Median increase above baseline in CD4(+) cell count was similar (q.d. group, +144 cells/mm(3); b.i.d. group, +146 cells/mm(3)), and the incidences of adverse events, disease progression, and HIV-associated conditions were comparable...
  5. doi Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    Lancet 379:2429-38. 2012
    ..We compared EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection...
  6. doi Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    Antivir Ther 15:711-20. 2010
    ..A pharmacokinetic trial was conducted to evaluate the potential for once-daily etravirine in antiretroviral regimens without and with darunavir/ritonavir...
  7. doi Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
    Roberto Ortiz
    Orlando Immunology Center, Orlando, Florida, USA
    AIDS 22:1389-97. 2008
    ....
  8. ncbi Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study
    Richard Elion
    George Washington University, Washington, DC, USA
    HIV Clin Trials 7:324-33. 2006
    ....
  9. ncbi Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    J Acquir Immune Defic Syndr 43:1-5. 2006
    ..GS-9137 is a potent low-nanomolar strand transfer inhibitor of HIV-1 integrase...
  10. ncbi Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis
    Anton L Pozniak
    Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 43:535-40. 2006
    ..Results through a 96-week extension phase are presented...
  11. pmc Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects
    Edwin DeJesus
    Orlando Immunology Center, Florida, USA
    Antimicrob Agents Chemother 50:3157-9. 2006
    ..A regimen of 700 mg of FPV BID plus 100 mg of RTV BID may be coadministered with NVP without dose adjustment...
  12. ncbi Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis
    Jose R Arribas
    Internal Medicine Service, Hospital de La Paz, Madrid, Spain
    J Acquir Immune Defic Syndr 47:74-8. 2008
    ..As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important...
  13. ncbi Advances in HIV therapeutics: news from the 4th International AIDS Society Conference
    Brian A Boyle
    AIDS Read 17:484-90. 2007
  14. ncbi Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection
    Peter Ruane
    Private Practice, Los Angeles, California, USA
    HIV Clin Trials 7:229-36. 2006
    ....
  15. doi Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients
    Jacob Lalezari
    Quest Clinical Research, San Francisco, CA 94115, USA
    J Infect Dis 197:721-7. 2008
    ..HGS004 is a fully human immunoglobulin (Ig) G4 monoclonal antibody against CC chemokine receptor 5 (CCR5) with robust in vitro activity against a diverse panel of CCR5-tropic human immunodeficiency virus type 1 (HIV-1) isolates...
  16. doi Adherence to enfuvirtide and its impact on treatment efficacy
    Jurgen Rockstroh
    Medizinische Klinik I, University of Bonn, Bonn, Germany
    AIDS Res Hum Retroviruses 24:141-8. 2008
    ..825). Adherence was high in patients receiving the self-injectable ARV enfuvirtide. In addition, the inclusion of ENF did not negatively impact adherence to the ARV regimen as a whole...
  17. doi Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine
    Edwin DeJesus
    Orlando Immunology Center, Orlando, Florida 32803, USA
    HIV Clin Trials 9:103-14. 2008
    ....
  18. doi Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study
    Richard Elion
    George Washington University, Washington, DC, USA
    HIV Clin Trials 9:152-63. 2008
    ....
  19. ncbi Update on antiretroviral therapy: the 15th CROI
    Brian A Boyle
    Department of International Medicine and Infectious Diseases, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, USA
    AIDS Read 18:273-8, C3. 2008
  20. ncbi Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus
    Gregory J Dore
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    J Infect Dis 189:1185-92. 2004
    ..Lamivudine has potent activity against both HIV-1 and HBV; however, lamivudine-resistance mutations in HBV frequently develop...
  21. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  22. doi Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  23. ncbi The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
    Joseph Eron
    Department of Medicine, Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
    Lancet 368:476-82. 2006
    ..Fosamprenavir-ritonavir has shown similar efficacy and safety to lopinavir-ritonavir when each is combined with two nucleoside reverse transcriptase inhibitors. We compared the two treatments directly in antiretroviral-naive patients...
  24. ncbi Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study
    Joseph C Gathe
    Therapeutic Concepts, P A, Houston, Texas, USA
    Clin Ther 28:745-54. 2006
    ....
  25. ncbi Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations
    Mike Youle
    Royal Free Hospital Centre for HIV Medicine, Royal Free Hospital, London, UK
    HIV Clin Trials 7:86-96. 2006
    ..g., ENF) for triple-class-experienced patients...
  26. ncbi A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
    Jacob P Lalezari
    Quest Clinical Research, San Francisco, CA 94115, USA
    AIDS 17:691-8. 2003
    ..Secondary objectives included the determination of enfuvirtide pharmacokinetics and antiviral activity and the immunological response to the enfuvirtide-containing regimen...
  27. ncbi A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults
    Jacob P Lalezari
    Quest Clinical Research and Mount Zion Hospital UCSF, San Francisco, Calif, USA
    Antivir Ther 8:279-87. 2003
    ..8% of patients in the control group. These results indicate that enfuvirtide has a favourable safety profile and is a promising new antiviral agent for HIV-infected patients who have been on previously failing ARV regimens...
  28. ncbi Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1
    Daniel R Kuritzkes
    Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, USA
    J Infect Dis 189:286-91. 2004
    ..We wished to determine the safety and anti-human immunodeficiency virus (HIV) type 1 activity of single doses of TNX-355, a humanized IgG4 anti-CD4 monoclonal antibody with potent activity against HIV-1 in vitro, in HIV-infected subjects...
  29. ncbi Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus
    Peter J Ruane
    Tower Infectious Diseases Medical Associates, Inc, Los Angeles, California 90049, USA
    Pharmacotherapy 24:307-12. 2004
    ..To compare the virologic activity of zidovudine monotherapy administered as 600 mg once/day versus 300 mg twice/day...
  30. ncbi SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients
    Joseph C Gathe
    Therapeutic Concepts, P A, Houston, Texas, USA
    AIDS 18:1529-37. 2004
    ..To compare the magnitude and durability of the antiviral response to fosamprenavir (FPV) plus ritonavir (RTV) once-daily (FPV/r QD) with nelfinavir twice-daily (NFV BID), each administered with abacavir and lamivudine twice-daily...
  31. ncbi Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    JAMA 292:191-201. 2004
    ..Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor...
  32. ncbi New nucleoside/nucleotide backbone options: a review of recent studies
    Peter J Ruane
    J Acquir Immune Defic Syndr 37:S21-9. 2004
    ....
  33. ncbi Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
    Margaret Johnson
    AIDS 19:153-62. 2005
  34. ncbi Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study
    Graeme J Moyle
    Chelsea and Westminster Hospital, HIV Clinic, London, United Kingdom
    J Acquir Immune Defic Syndr 38:417-25. 2005
    ..7%). ABC administered once daily in combination with 3TC and EFV administered once daily was non-inferior to the ABC twice-daily dosing schedule when combined with 3TC and EFV over 48 weeks...
  35. ncbi 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
    Margaret Johnson
    Royal Free Hospital, London, UK
    AIDS 20:711-8. 2006
    ..Results of extended follow-up to 96 weeks are presented...
  36. ncbi Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    N Engl J Med 354:251-60. 2006
    ..Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere...
  37. ncbi Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients
    Michael G Sension
    Comprehensive Care Center, Fort Lauderdale, Florida 33311, USA
    HIV Clin Trials 3:361-70. 2002
    ....
  38. ncbi Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL)
    Nestor Sosa
    Social Security Hospital, Panama City, Panama
    J Acquir Immune Defic Syndr 40:422-7. 2005
    ....
  39. ncbi Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial
    Mark S Sulkowski
    J Acquir Immune Defic Syndr 39:504-6. 2005
  40. ncbi Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients
    Martin Markowitz
    The Aaron Diamond AIDS Research Center, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 39:257-64. 2005
    ..The ESS40013 study tested 4-drug induction followed by 3-drug maintenance as initial antiretroviral therapy (ART) to reduce HIV RNA rapidly and then to simplify to an effective yet more convenient and tolerable regimen...
  41. ncbi Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
    Margaret Johnson
    Royal Free Hospital, London, UK
    AIDS 19:685-94. 2005
    ....
  42. ncbi Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects
    Melanie Thompson
    AIDS Research Consortium of Atlanta, Atlanta, Georgia 30308, USA
    AIDS 20:397-404. 2006
    ..To investigate the pharmacokinetics, safety/tolerability and antiviral activity of enfuvirtide administered once-daily (QD) versus twice-daily (BID)...
  43. doi First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America
    Benjamin Young
    Division of General Internal Medicine, University of Colorado, Rose Medical Center, Denver, Colorado 80220, USA
    AIDS 22:1673-5. 2008
    ....